Trial Profile
A Open-Label Extension Study Of CP-690,550 As Maintenance Therapy In Patients With Crohn's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Feb 2019 Results assessing long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease, published in the Alimentary Pharmacology and Therapeutics
- 16 Aug 2016 Status changed from recruiting to completed.
- 16 Aug 2016 This trial was completed in Bulgaria (End date: 25 Jul 2016).